title: The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine.
abstract: LD78alpha and LD78beta are 2 highly related nonallelic genes that code for different isoforms of the human CC chemokine macrophage inflammatory protein-1alpha (MIP-1alpha). Two molecular forms of natural LD78beta (7.778 and 7.793 kDa) were identified from conditioned media of stimulated peripheral blood mononuclear cells. Although LD78alpha and LD78beta only differ in 3 amino acids, both LD78beta variants were 100-fold more potent chemoattractants for mouse lymphocytes than was LD78alpha. On the contrary, LD78beta was only 2-fold more efficient than LD78alpha in chemoattracting human lymphocytes and monocytes. Using CC chemokine receptor-transfected cells, both molecular forms of LD78beta proved to be much more potent than LD78alpha in inducing an intracellular calcium rise through CCR5. Compared with LD78alpha and RANTES, this preferential binding of LD78beta to CCR5 resulted in a 10- to 50-fold higher potency in inhibiting infection of peripheral blood mononuclear cells by CCR5-using (R5) HIV-1 strains. To date, LD78beta is the most potent chemokine for inhibiting HIV-1 infection, and can be considered as a potentially important drug candidate for the treatment of infection with R5 HIV-1 strains.
authors.affiliation: Laboratory of Molecular Immunology, Rega Institute for Medical Research, University of Leuven, B-3000 Leuven, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Menten
authors.forename: S
authors.initials: S
authors.lastname: Struyf
authors.forename: E
authors.initials: E
authors.lastname: Schutyser
authors.forename: A
authors.initials: A
authors.lastname: Wuyts
authors.forename: E
authors.initials: E
authors.lastname: De Clercq
authors.forename: D
authors.initials: D
authors.lastname: Schols
authors.forename: P
authors.initials: P
authors.lastname: Proost
authors.forename: J
authors.initials: J
authors.lastname: Van Damme
mesh_terms: D000818:Animals; D002460:Cell Line; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D018946:Chemokine CCL5 / Q000494:pharmacology; D015658:HIV Infections / Q000517:prevention & control / Q000628:therapy; D015497:HIV-1 / Q000187:drug effects* / Q000472:pathogenicity; D006801:Humans; D066298:In Vitro Techniques; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology / Q000821:virology; D019402:Macrophage Inflammatory Proteins / Q000235:genetics* / Q000302:isolation & purification / Q000494:pharmacology*; D051379:Mice; D020033:Protein Isoforms / Q000235:genetics / Q000302:isolation & purification / Q000494:pharmacology; D019713:Receptors, CCR5 / Q000819:agonists* / Q000235:genetics; D014162:Transfection
chemical_list: D054405:Chemokine CCL3; D054407:Chemokine CCL4; D018946:Chemokine CCL5; D019402:Macrophage Inflammatory Proteins; D020033:Protein Isoforms; D019713:Receptors, CCR5